Janssen Search
Search results
Our Approach to R&D
The World Is Our Lab: A Collaborative Approach to Research & Development Innovation Research & Development. Creativity & Fresh Ideas. Science & Solutions. Collaboration is in our DNA. We know where it has taken us. We know it can take us ...
eMeds: The Future of Clinical Trial Data
eMeds: Integrated Platform to Transform Medication & Adherence Management The current system for managing clinical supplies is inefficient. Patients must search through multi‐language medication label booklets for dosing instructions, and doses are ...
Peter M. DiBattiste, M.D.
Peter M. DiBattiste, M.D. is responsible for co-leading the Cardiovascular & Metabolism (CVM) Therapeutic Area at Janssen Research & Development, setting the strategy and leading the team in discovery and development of novel therapeutics for ...
Thomas M. Luby, Ph.D.
Thomas Luby, Ph.D. is a Senior Director of New Ventures at Johnson & Johnson Innovation, Boston, focusing on early investments and collaborations in Neuroscience, Cardiovascular & Metabolism and Infectious Disease. Prior to joining the Johnson ...
Discovering Solutions to Infectious Diseases
Discovery Article Type: Infectious Diseases & Vaccines Towards a world free of infectious diseases Our scientists aspire to discover and develop innovative medicines and vaccines that aim to treat some of the world’s most life-threatening infectious ...
Janssen Never Stops
Our Commitment Watch this video and you'll have a better idea of what we do every day to prevent, treat, cure, and stop some of the most devastating and complex diseases of our time. FOR U.S. PATIENTS PATIENT RESOURCES ACCESS AND AFFORDABILITY ...
Ming Dong
MING DONG GLOBAL HEAD SENSORS & WEARABLES WORLD WITHOUT DISEASE ACCELERATOR Ming leads the Sensors and Wearables team within the World Without Disease Accelerator (WWDA), which is focused on non-invasive clinically significant sensing systems embedded ...
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
Aug 23, 2024 Belgium First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR 3 alterations Approval based on THOR results, showing 36 percent ...
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Apr 22, 2024 Belgium Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse [1] Approval is based on results from the PHASE 3 CARTITUDE-4 study, in ...
Late-breaking results show nipocalimab significantly improves Sjögren’s disease activity in a Phase 2 study
Jun 15, 2024 Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren’s disease is a chronic, debilitating, and prevalent ...